+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Global Fabry Disease Treatment Market by Treatment Type (Chaperone Treatment, Enzyme Replacement Therapy, Organ-Specific Treatment), Drugs (Agalsidase Beta, Migalastat, Pipeline Drugs), Route of Administration - Forecast 2024-2030

  • PDF Icon

    Report

  • 184 Pages
  • March 2024
  • Region: Global
  • 360iResearch™
  • ID: 4989675
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Fabry Disease Treatment Market size was estimated at USD 2.50 billion in 2023, USD 2.71 billion in 2024, and is expected to grow at a CAGR of 8.47% to reach USD 4.41 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Fabry Disease Treatment Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Fabry Disease Treatment Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Fabry Disease Treatment Market, highlighting leading vendors and their innovative profiles. These include Amicus Therapeutics Inc., Avrobio Inc., BioMarin, Biosidus S.A., Digestive Care, Inc., GlaxoSmithKline PLC, Idorsia Pharmaceuticals Ltd., ISU Abxis Co Ltd., JCR Pharmaceuticals Co Ltd., Leadiant Biosciences, Inc., Nestle Health Science, Pfizer Inc., Protalix Biotherapeutics Inc., Sanofi S.A., and Takeda Pharmaceutical Company Limited.

Market Segmentation & Coverage

This research report categorizes the Fabry Disease Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Treatment Type
    • Chaperone Treatment
    • Enzyme Replacement Therapy
    • Organ-Specific Treatment
    • Substrate Reduction Therapy
  • Drugs
    • Agalsidase Beta
    • Migalastat
    • Pipeline Drugs
  • Route of Administration
    • Intravenous
    • Oral
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as

  1. What is the market size and forecast of the Fabry Disease Treatment Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Fabry Disease Treatment Market?
  3. What are the technology trends and regulatory frameworks in the Fabry Disease Treatment Market?
  4. What is the market share of the leading vendors in the Fabry Disease Treatment Market?
  5. Which modes and strategic moves are suitable for entering the Fabry Disease Treatment Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Fabry Disease Treatment Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing demand for messenger RNA as a treatment modality for Fabry disease
5.1.1.2. Increasing number of clinical trials
5.1.1.3. Growing incidences of genetic disorders and increasing awareness
5.1.2. Restraints
5.1.2.1. Lack of awareness about advancements with respect to treatments for Fabry disease
5.1.3. Opportunities
5.1.3.1. Ongoing research and development for the treatment of Fabry disease
5.1.3.2. Increasing healthcare expenditure and improving infrastructure in emerging economies
5.1.4. Challenges
5.1.4.1. Limitations in adopting new technologies in certain countries
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
6. Fabry Disease Treatment Market, by Treatment Type
6.1. Introduction
6.2. Chaperone Treatment
6.3. Enzyme Replacement Therapy
6.4. Organ-Specific Treatment
6.5. Substrate Reduction Therapy
7. Fabry Disease Treatment Market, by Drugs
7.1. Introduction
7.2. Agalsidase Beta
7.3. Migalastat
7.4. Pipeline Drugs
8. Fabry Disease Treatment Market, by Route of Administration
8.1. Introduction
8.2. Intravenous
8.3. Oral
9. Americas Fabry Disease Treatment Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Fabry Disease Treatment Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Fabry Disease Treatment Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.2. Market Share Analysis, By Key Player
12.3. Competitive Scenario Analysis, By Key Player
13. Competitive Portfolio
13.1. Key Company Profiles
13.1.1. Amicus Therapeutics Inc.
13.1.2. Avrobio Inc.
13.1.3. BioMarin
13.1.4. Biosidus S.A.
13.1.5. Digestive Care, Inc.
13.1.6. GlaxoSmithKline PLC
13.1.7. Idorsia Pharmaceuticals Ltd.
13.1.8. ISU Abxis Co Ltd.
13.1.9. JCR Pharmaceuticals Co Ltd.
13.1.10. Leadiant Biosciences, Inc.
13.1.11. Nestle Health Science
13.1.12. Pfizer Inc.
13.1.13. Protalix Biotherapeutics Inc.
13.1.14. Sanofi S.A.
13.1.15. Takeda Pharmaceutical Company Limited
13.2. Key Product Portfolio
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing
List of Figures
FIGURE 1. FABRY DISEASE TREATMENT MARKET RESEARCH PROCESS
FIGURE 2. FABRY DISEASE TREATMENT MARKET SIZE, 2023 VS 2030
FIGURE 3. FABRY DISEASE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. FABRY DISEASE TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. FABRY DISEASE TREATMENT MARKET DYNAMICS
FIGURE 7. FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2030 (%)
FIGURE 8. FABRY DISEASE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2030 (%)
FIGURE 10. FABRY DISEASE TREATMENT MARKET SIZE, BY DRUGS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
FIGURE 12. FABRY DISEASE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 14. AMERICAS FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 16. UNITED STATES FABRY DISEASE TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. ASIA-PACIFIC FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA FABRY DISEASE TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. FABRY DISEASE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 22. FABRY DISEASE TREATMENT MARKET SHARE, BY KEY PLAYER, 2023

Companies Mentioned

  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • BioMarin
  • Biosidus S.A.
  • Digestive Care, Inc.
  • GlaxoSmithKline PLC
  • Idorsia Pharmaceuticals Ltd.
  • ISU Abxis Co Ltd.
  • JCR Pharmaceuticals Co Ltd.
  • Leadiant Biosciences, Inc.
  • Nestle Health Science
  • Pfizer Inc.
  • Protalix Biotherapeutics Inc.
  • Sanofi S.A.
  • Takeda Pharmaceutical Company Limited

Methodology

Loading
LOADING...

Table Information